

Awards with budget start dates within January 2014

by Principal Investigator

<i>PI</i>	<i>Title</i> <i>Agency Name</i> <i>Award ID</i>	<i>Direct Costs</i> <i>Indirect Costs</i>	<i>Total Costs</i>	<i>Budget Dates</i> <i>Project Dates</i>
COM				
<u>EMERGENCY MEDICINE</u>				
Holmes, Talmage M	Adult Emergency Department Patients with Acute Asthma and Survey of Local Asthma Centers: 36th Multicenter Airway Research Collaboration (MARC-36) Study Massachusetts General Hospital MARC-36	\$3,500 \$0	\$3,500	1/3/2014 - 1/1/4000 1/3/2014 - 1/1/4000
<u>MEDICINE</u>				
Abul-Ezz, Sameh R.	An open-label, phase 2 study to treat patients with renal allograft and polyoma BK viremia to prevent polyoma BK viremia, polyoma BK nephropathy and renal allograft rejection. Polyoma BK	\$103,245 \$30,973	\$134,218	1/14/2014 - 1/1/4000 1/14/2014 - 1/1/4000
Anderson, Paula J	Therapeutic Development Center Cystic Fibrosis Foundation ANDERS14Y0	\$80,595 \$6,448	\$87,043	1/1/2014 - 12/31/2014 1/1/2009 - 12/31/2014
<u>OBSTETRICS AND GYNECOLOGY</u>				
Zorn, Kristin	Preventing Endometrial Cancer through Outreach to Lynch Syndrome Families Foundation for Gynecologic Oncology na	\$10,000 \$0	\$10,000	1/6/2014 - 12/30/2014 1/6/2014 - 12/30/2014
Zorn, Kristin	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 (IND #78,416) in Combination with Pegylated Liposomal Doxorubicin (Doxil®) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer VentiRx VTX237	\$11,200 \$2,800	\$14,000	1/2/2014 - 1/1/2029 1/2/2014 - 1/21/2029
<u>PHARMACOLOGY</u>				
Rusch, Nancy J	AHA-Vascular TRPC3 Channels as Antihypertensive Targets American Heart Association (SouthWest Affiliate) 13GRNT14590001	\$63,636 \$6,364	\$70,000	1/1/2014 - 12/31/2014 1/1/2013 - 12/31/2014
Singh, Sharda P	Mitochondrial-nuclear signaling for protection against doxorubicin cardiotoxicity American Heart Association (SouthWest Affiliate) 14GRNT18890084	\$63,636 \$6,364	\$70,000	1/1/2014 - 12/31/2014 1/1/2014 - 12/31/2015
<u>PHYSIOLOGY & BIOPHYSICS</u>				
Lupashin, Vladimir	Characterization of mammalian COG complex-interacting Golgi trafficking machinery NIH/NIGMS 2 R01 GM083144-06	\$250,000 \$115,244	\$365,244	1/1/2014 - 11/30/2014 8/1/2008 - 11/30/2017

<i>PI</i>	<i>Title</i> <i>Agency Name</i> <i>Award ID</i>	<i>Direct Costs</i> <i>Indirect Costs</i>	<i>Total</i> <i>Costs</i>	<i>Budget Dates</i> <i>Project Dates</i>
<u>UROLOGY</u>				
Katz, Matthew D	S1107, Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma NIH/NCI S1107	\$5,000 \$0	\$5,000	1/7/2014 - 1/6/4000 1/7/2014 - 1/6/4000
COP				
<u>PHARMACY PRACTICE</u>				
Payakachat, Nalin	Mapping Clinical Outcomes to Preference-based Measures from the NDAR Database NIH/NIMH 1 R03 MH102495-01	\$50,000 \$24,500	\$74,500	1/15/2014 - 1/31/2015 1/15/2014 - 1/31/2016
CPH				
<u>COLLEGE OF PUBLIC HEALTH</u>				
Yeary, Karen H	Faith Academic Initiative for Transforming Health (FAITH) in the Delta NIH/National Center on Minority Health and Health 5 R24 MD007923-02	\$224,969 \$78,395	\$303,364	1/1/2014 - 12/31/2014 1/1/2013 - 12/31/2015
MYEL				
<u>MYELOMA INSTITUTE</u>				
JETHAVA, Yogesh	A Phase 3, Randomized, Double Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma. Millennium MLN9708	\$24,401 \$6,100	\$30,501	1/14/2014 - 1/13/2029 1/14/2014 - 1/13/2029